Search

TG Therapeutics Inc

Suletud

SektorTervishoid

64.4 0.36

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

63.94

Max

64.62

Põhinäitajad

By Trading Economics

Sissetulek

48M

55M

Müük

20M

260M

P/E

Sektori keskmine

94.597

68.089

Aktsiakasum

0.35

Kasumimarginaal

21.337

Töötajad

399

EBITDA

64M

86M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+18.43% upside

Turustatistika

By TradingEconomics

Turukapital

525M

9.7B

Eelmine avamishind

64.04

Eelmine sulgemishind

64.4

TG Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2026, 21:13 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading, reflecting broader market declines influenced by the Federal Reserve's financial stability report.

12. nov 2026, 23:06 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading following fluctuations earlier in the session.

11. nov 2026, 23:06 UTC

TG Therapeutics, Inc. is trading slightly lower in after-market hours after peaking earlier.

10. nov 2026, 21:03 UTC

Social Media
News

TG Therapeutics stock advanced after Evercore ISI maintained its Outperform rating and J.P. Morgan raised its global revenue guidance to $1 billion.

9. nov 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. is trading slightly higher in after-market hours following the completion of a $100 million share repurchase program, buying back 3.5 million shares.

6. nov 2026, 22:51 UTC

TG Therapeutics, Inc. is trading modestly higher in after-market hours, reflecting broader market gains following strong U.S. labor market data for October.

5. nov 2026, 23:03 UTC

TG Therapeutics, Inc. shares advanced modestly during after-market hours on Thursday, fluctuating from negative territory to a high nearing 1%.

4. nov 2026, 23:26 UTC

TG Therapeutics, Inc. is roughly flat in after-market trading, slightly declining from an early high but remaining above its 20-day moving average.

3. nov 2026, 22:51 UTC

TG Therapeutics, Inc. is advancing in after-market trading, moving higher alongside the broader market following a recovery from an initial dip after Tuesday's close.

2. nov 2026, 23:51 UTC

TG Therapeutics, Inc. shares advanced in after-market trading, moving higher alongside the broader market, despite some volatility during the session.

31. okt 2026, 00:02 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, reaching its highest cumulative return of the day and significantly surpassing Friday's close.

30. okt 2026, 23:31 UTC

TG Therapeutics, Inc. shares traded modestly higher during after-market hours on Friday, continuing a trend of higher daily closes since the prior close.

29. okt 2026, 22:26 UTC

TG Therapeutics, Inc. is experiencing a notable decline in after-market trading, retracing from earlier gains and marking a significant drop since Thursday's close.

28. okt 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. shares are trading lower in after-market hours ahead of earnings on Monday, fluctuating between a loss of over two percent and a slight gain.

27. okt 2026, 20:51 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, recovering from earlier losses to reach a notable peak above its 20-day moving average.

26. okt 2026, 20:13 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, following three consecutive sessions of gains and an unusual lack of variation.

23. okt 2026, 20:03 UTC

Social Media
News

TG Therapeutics announced initial Phase 1 study results showing 89% of participants with progressive multiple sclerosis had stable or improved disability scores at Day 90.

22. okt 2026, 20:07 UTC

TG Therapeutics Inc shares fell slightly, retracing from an early peak and ending near the lower end of their one-month range.

21. okt 2026, 19:36 UTC

Social Media
News

TG Therapeutics presented new clinical data for BRIUMVI at the MSToronto2026 conference, showing 88% of patients free from disability progression after continuous treatment.

20. okt 2026, 22:36 UTC

Social Media

TG Therapeutics Inc is trading lower in after-market hours, having retraced from an earlier high and positioned near the lower end of its one-month trading range.

19. okt 2026, 20:07 UTC

Social Media

Shares of TG Therapeutics Inc are declining, finishing well below the 20-day moving average and near the lower end of the one-month range.

16. okt 2026, 19:53 UTC

Social Media

TG Therapeutics Inc shares are declining sharply, trading well below their 20-day moving average and near the lower end of their one-month range.

15. okt 2026, 20:07 UTC

TG Therapeutics Inc shares advanced, peaking in the late morning and settling near the day's high, remaining above its 20-day moving average.

14. okt 2026, 23:21 UTC

TG Therapeutics Inc shares declined in after-market trading, moving lower alongside the broader market amid significant declines in technology stocks and rising crude oil prices.

12. okt 2026, 19:56 UTC

Social Media
News

TG Therapeutics published a five-year study showing BRIUMVI has a lower risk of disability progression compared to ocrelizumab and ofatumumab in relapsing multiple sclerosis.

10. okt 2026, 00:01 UTC

TG Therapeutics Inc shares are trading modestly higher in after-market hours, continuing a trend of four consecutive sessions finishing higher.

9. okt 2026, 23:20 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, having fluctuated between a decline and a slight gain since Friday's close.

8. okt 2026, 19:15 UTC

News
Social Media
Event

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7. okt 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6. okt 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

TG Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

18.43% tõus

12 kuu keskmine prognoos

Keskmine 76.4 USD  18.43%

Kõrge 86 USD

Madal 71 USD

Põhineb 6 Wall Streeti analüütiku instrumendi TG Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

5

Osta

0

Hoia

1

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat